Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL

B细胞急性淋巴细胞白血病(B-ALL)中白血病起始活性需要干细胞样重编程。

阅读:3
作者:Vincent Fregona ,Manon Bayet ,Mathieu Bouttier ,Laetitia Largeaud ,Camille Hamelle ,Laura A Jamrog ,Naïs Prade ,Stéphanie Lagarde ,Sylvie Hebrard ,Isabelle Luquet ,Véronique Mansat-De Mas ,Marie Nolla ,Marlène Pasquet ,Christine Didier ,Ahmed Amine Khamlichi,Cyril Broccardo ,Éric Delabesse # ,Stéphane J C Mancini #,Bastien Gerby

Abstract

B cell acute lymphoblastic leukemia (B-ALL) is a multistep disease characterized by the hierarchical acquisition of genetic alterations. However, the question of how a primary oncogene reprograms stem cell-like properties in committed B cells and leads to a preneoplastic population remains unclear. Here, we used the PAX5::ELN oncogenic model to demonstrate a causal link between the differentiation blockade, the self-renewal, and the emergence of preleukemic stem cells (pre-LSCs). We show that PAX5::ELN disrupts the differentiation of preleukemic cells by enforcing the IL7r/JAK-STAT pathway. This disruption is associated with the induction of rare and quiescent pre-LSCs that sustain the leukemia-initiating activity, as assessed using the H2B-GFP model. Integration of transcriptomic and chromatin accessibility data reveals that those quiescent pre-LSCs lose B cell identity and reactivate an immature molecular program, reminiscent of human B-ALL chemo-resistant cells. Finally, our transcriptional regulatory network reveals the transcription factor EGR1 as a strong candidate to control quiescence/resistance of PAX5::ELN pre-LSCs as well as of blasts from human B-ALL.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。